Subscribe to Search results

Dr Saad Al-Ismail was one of many clinicians that gave evidence to the inquiry who argued that patients were informed of the risks of hepatitis.

Published on:

Inquiry updates timetable and opens registration for September hearings

Published on:

Professor Bloom held that during the 1970s that although most patients were infected with NANB Hepatitis, patients did not suffer from clinical liver disease.

Published on:

Professor Bloom held that during the 1980s most haemophilia specialists recognised the risk of hepatitis in haemophiliacs after treatment with concentrates, however the general belief was that bleeding was still the primary cause of death amongst patients.

Published on:

Professor Bloom stated that by 1 January 1985, all Haemophilia Centres should have received the AIDS advisory document.

Published on:

The AIDS Advisory document recorded that heat-treated commercial factor products were available. On the subject, Professor Bloom stated that during the early 1980s, several observers noted that there appeared to be a reduced risk of HIV infection and/or immunological abnormalities in patients with haemophilia B compared to those with haemophilia A.

Published on:

Following the fifth meeting by the AIDS Group, on 17 June 1985, more centres had transitioned to using commercial heat-treated Factor 9.

Published on:

Professor Bloom held, that around 1983-1984, that it was not necessary to inform patients or the parents of patients of the risks of AIDS.

Published on:

Professor Bloom held that he existence of the viruses causing serum hepatitis was well known to doctors caring for haemophiliacs during the 1960's, 1970's and later.

Published on:

The reference centre at the Manchester Royal Infirmary was part of a regional haemophilia service in North West England, which included Manchester Children's Hospital and the Lancaster Haemophilia Centre.

Published on:

Most patients being treated for haemophilia who were treated at the Manchester Royal Infirmary would have been informed that there was a high likelihood of them having AIDS. They were informed either by letter or through routine appointments.

Published on:

One of the aims of the appointment of Dr Wensley was to create a better understanding with the RTC and "a greater availability of cryoprecipitate and better treatment for all
haemophiliacs."

Published on:

Manchester Royal Infirmary's role was described in an article: "today with modern methods of treatment and patient assessment.. haemophiliacs are able to lead a near-normal, albeit hazardous, life. Their great salvation comes in small plastic bags containing as the cryoprecipitate."

Published on:

Dr Delamore preferred to administer cryoprecipitate but observed that if freeze-dried concentrate could be altered to be dissolved more easily and in smaller volume, "we would probably choose that preparation in preference to cryoprecipitate."

Published on:

The annual return for 1976 showed substantial use of cryoprecipitate, NHS concentrate and Kryobulin, with some use of Hemofil. Both FEIBA and porcine Factor 8 were also used in Manchester Haemophilia Centre.

Published on:

1977 saw an increase in the volume of NHS concentrate used at the Manchester Royal Infirmary, but a greater volume of commercial as well.

Published on:

In 1978, NHS concentrate was used in greatest measure at the Manchester Royal Infirmary, but significant quantities of commercial concentrates and cryoprecipitate were also used.

Published on:

In 1979, NHS concentrate was used in the greatest measure at the Manchester Royal Infirmary but with large quantities of commercial concentrates and cryoprecipitate all used as well.

Published on:

It was observed that usage of cryoprecipitate in the North West region remained high in comparison with the national position, due to the policies adopted by the regional haemophilia service.

Published on:

Dr Wensley recorded that the NHS concentrate compared well with commercial. and that he was gradually changing his home treatment patients from commercial to NHS concentrate, with the plan that commercial concentrate would then be used only in operations.

Published on: